However, therapeutic resistance may arise through loss of ER expression, mutations in ER or overexpression of alternative breast cancer-driving pathways such as ERBB1/EGFR (Garcia-Becerra et al., 2012; Clarke et al., 2015; Ma et al., 2015). This evidence concerns the gene EGFR and breast cancer.